Investigation of PON1192 and PON1 55 polymorphisms in ovarian cancer patients in Turkish population

In Vivo

Volumn 23, Issue 3, 2009, Pages 421-424

  Arpaci, Aytaç ^a   Görmüş, Uzay ^a   Dalan, Burak ^a   Berkman, Sinan ^b   Isbir, Turgay ^a,b  

^a Institute for Experimental Medical Research   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Ovarian cancer; Paraoxonase; PCR; Polymorphism; RFLP

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; ARYLDIALKYLPHOSPHATASE; PON1 PROTEIN, HUMAN; PRIMER DNA;

ADULT; AGAR GEL ELECTROPHORESIS; ALLELE; ARTICLE; CANCER PATIENT; CHI SQUARE TEST; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; POLYMERASE CHAIN REACTION; PROTEIN POLYMORPHISM; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK FACTOR; SMOKING; TURKEY (REPUBLIC); GENETIC POLYMORPHISM; GENETICS; NUCLEOTIDE SEQUENCE; OVARY TUMOR;

ARYLDIALKYLPHOSPHATASE; BASE SEQUENCE; DNA PRIMERS; FEMALE; HUMANS; OVARIAN NEOPLASMS; POLYMORPHISM, GENETIC; TURKEY;

EID: 67649679294     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Levine DA and Boyd J: The androgen receptor and genetic susceptibility to ovarian cancer: results from a case series. Cancer Res 61: 908-911, 2001.
2. Burdon RH, Gill V and Rice Evans C: Oxidative stress and tumor cell proliferation. Free Radic Res Commun 11: 65-76, 1990.
3. Goldstein BD, Czerniecki B and Witz G: The role of free radicals in tumor promotion. Environ Health Perspect 81: 55-57, 1986.
4. Dizdaroglu M: Chemical determination of free radical-induced damage to DNA. Free Radic Biol Med 10: 225-242,1991.
5. Ness RB and Cottreau C: Possible role of ovarian epithelial inflammation in ovarian cancer. J Nat Cancer Inst 91: 1459-1467,1999.
6. Harel M, Aharoni A, Gaidukov L, Brumshtein B, Khersonsky 0, Meged R, Dvir H, Ravelli RB, McCarthy A, Toker L, Silman 1, Sussman JL and Tawfik DS: Structure and evolution of the serum paraoxonase family of detoxifying and anti-atherosclerotic enzymes. Nat Struct Mol Biol 11: 412-419, 2004.
7. Mackness MI, Mackness B, Durrington PN, Fogelman AM, Berliner J, Lusis AJ, Navab M, Shin D and Fonarow GC: Paraoxonase and coronary heart disease. Curr Opin Lipidol 9(4): 319-324, 1998.
8. Billecke S, Draganov D, Counsell R, Stetson P, Watson C, Hsu C and La Du BN: Human serum paraoxonase (PONI) isozymes Q and R hydrolyze lactones and cyclic carbonate esters. Drug Metab Dispos 28: 1335-1342, 2000.
9. Diplock AT, Rice-Evans AC and Burton RH: Is there a significant role for lipid peroxidation in the causation of malignancy and for antioxidants in cancer prevention? Cancer Res 54: 19525-19565, 1994.
10. Rao MN, Marmillot P, Gong M, Palmer DA, Seeff LB, Strader DB and Lakshman MR: Light, but not heavy alcohol drinking, stimulates paraoxonase by up-regulating liver mRNA in rats and humans. Metabolism 52: 1287-1294, 2003.
11. Martinez G, Loureiro A, Marques S, Miyamoto S, Yamaguchi LF, Onuki J, Almeida EA, Garcia CC, Barbosa LF, Medeiros MH and Di Mascio P: Oxidative and alkylating damage in DNA. Mutat Res 544: 115-127, 2003.
12. Kenneth AC: Dietary antioxidants during cancer chemotherapy: impact on chemotherapeutic effectiveness and development of side effects. Nutr Cancer 37: 1-18, 2000.
13. Humbert R, Adler DA, Disteche CM, Hassett C, Omiecinski CJ and Furlong CE: The molecular basis of the human serum paraoxonase polymorphisms. Nat Genet 3: 73-76,1993.
14. Aviram M, Hardak E, Vaya J, Mahmood S, Milo S, Hoffman A, Billicke S, Draganov D and Rosenblat M: Human serum paraoxonase (PONI) Q and R selectively decrease lipid peroxides in human coronary and carotid arteriosclerotic lesions. Circulation 101: 2510-2517, 2000
15. Mackness BM, Mackness MI, Airol S, Turkie W and Durrington PN: Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification. FEBS Lett 423:57-60, 1998.
16. Blatter Garin M, James R, Dussoix P, Blanche H, Passa P, Froguel P and Ruiz J: Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. J Clin Invest 99: 62-66, 1997.
17. Mackness MI, Mackness B, Durrington PN, Connely PW and Hegele RA: Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins. Cur Opin Lipid 7: 69-76, 1996.
18. Aviram M, Billecke S, Sorenson R, Bisgaier C, Newton R, Rosenblat M, Erogul J, Hsu C, Dunlop C and La Du BN: Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities: selective action of human paraoxonase allozymes Q and R. Arterioscler Thromb Vase Biol 18: 1617-1624, 1998.
19. Leviev I, Deakin S and James R: Decreased stability of the M54 isoform of paraoxonase as a contributory factor to variations in human serum paraoxonase concentrations. Journal of Lipid Res 42: 528-535,2001.
20. Adkins S, Gan KN, Mody M and La Du BN: Molecular basis for the polymorphic forms of human serum paraoxonase/ arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. Am J Hum Genet 52: 598-608, 1993.
21. Van Der Logt EM, Janssen CH, Van Hooijdonk Z, Roelofs HM, Wobbes T, Nagengast FM and Peters WH: No association between genetic polymorphisms in NAD(P)H oxidase p22phox and paraoxonase 1 and colorectal cancer risk. Anticancer Res 25: 1465-1470,2005.
22. Antognelli C, Mearini L, Talesa VN, Giannantoni A and Mearini E: Association of CYP17, GSTP1, and PON1 polymorphisms with the risk of prostate cancer. Prostate 63: 240-251, 2005.
23. Ferre N, Camps J, Fernandez-Ballart J, Arija V, Murphy MM and Ceruelo S: Regulation of serum paraoxonase activity by genetic, nutritional and lifestyle factors in the general population. Clin Chem 49: 1491-1497, 2003.
24. Senti M, Tomas M, Anglada R, Eiosua R, Marrugat J and Covas MI: Inter-relationship of smoking, paraoxonase activity, and leisure time physical activity: a population-based study. Eur J Int Med 14: 178-184,2003.
25. Lurie G, Wilkens LR, Thompson PJ, McDuffie KE, Carney ME, Terada KY and Goodman MT: Genetic polymorphisms in the paraoxonase 1 gene and risk of ovarian epithelial carcinoma. Cancer Epidemiol Biomarkers Prev 17: 2070-2077, 2008.